[The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
The research concerning with the pathogenesis of amyotrophic lateral sclerosis (ALS) has been in steady progress in the last 10 years, including discovery of SOD mutation in familial ALS. Riluzole, by its inhibiting excitatory amino acid release, is the only drug, which has been demonstrated the neuroprotective activity in the randomised double-blind placebo-controlled clinical trials in patients with ALS, although many other clinical therapeutic trials for ALS patients has been carried out. We discussed the clinical trials being the under way, especially SR57746A, (1-[2-(naphth-2-yl)ethy]-4-(3-trifluoromethyl phenyl)-1, 2, 5, 6-tetrahydro-pyridine, hydrochloride), a non-peptide compound which has been shown to exhibit a wide range of neurotrophic effects both in vitro and in vivo, and its phase II study in Japan and two kinds of phase III studies ongoing in the United States, Canada and Europe. We also introduced the clinical guideline for practice and care of ALS patients proposed by American Academy of Neurology, expecting to establish clinical guideline to be applicable to Japanese cases.
Moriwaka
F
F
Department of Neurology, Hokkaido University School of Medicine.
Tashiro
K
K
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy / Q000209:etiology; D018849:Controlled Clinical Trials as Topic; D015195:Drug Design; D018846:Excitatory Amino Acids / Q000378:metabolism; D006801:Humans; D009281:Naphthalenes / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000627:therapeutic use; D019782:Riluzole / Q000494:pharmacology / Q000627:therapeutic use
D018846:Excitatory Amino Acids; D009281:Naphthalenes; D018696:Neuroprotective Agents; D011725:Pyridines; D019782:Riluzole; C462299:xaliproden